Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus QMF149 in asthma
2015-002899-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing QVM149, QMF149 and Salmeterol + fluticasone propionate (3 arms). Primary endpoints: Trough FEV1 over 26 weeks and Trough FEV1 at week 52. Started Nov 2015; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoateatectura breezhalersalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-002899-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002899-25.